Published in PLoS One on May 19, 2014
Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells. Expert Rev Clin Immunol (2015) 0.81
HIV-related proteins prolong macrophage survival through induction of Triggering receptor expressed on myeloid cells-1. Sci Rep (2017) 0.77
TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine. Am J Physiol Lung Cell Mol Physiol (2015) 0.77
Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD. BMC Pulm Med (2015) 0.77
Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. Mediators Inflamm (2017) 0.75
TREM-1low is a novel characteristic for tumor-associated macrophages in lung cancer. Oncotarget (2016) 0.75
TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun (2016) 0.75
Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. ACS Nano (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Inflammation and cancer. Nature (2002) 53.78
Cancer-related inflammation. Nature (2008) 34.21
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 13.44
Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 12.21
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
The new lung cancer staging system. Chest (2009) 6.30
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol (2000) 5.37
TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature (2001) 5.24
Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell (2011) 4.02
Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther (2004) 3.40
Cancer related inflammation: the macrophage connection. Cancer Lett (2008) 2.88
TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol (2009) 2.44
Inflammatory cells and cancer: think different! J Exp Med (2001) 2.42
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Functional genomics of silencing TREM-1 on TLR4 signaling in macrophages. Am J Physiol Lung Cell Mol Physiol (2007) 1.82
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer (2001) 1.65
From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology (2008) 1.57
A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila) (2008) 1.41
Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol (2010) 1.39
Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology (1999) 1.38
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A (2010) 1.36
The TREM-1/DAP12 pathway. Immunol Lett (2007) 1.33
Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur J Immunol (2007) 1.32
Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol (2008) 1.30
The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res (2012) 1.27
TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med (2007) 1.24
Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res (2008) 1.22
Regular aspirin use and lung cancer risk. BMC Cancer (2002) 1.15
Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol (2010) 1.12
Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer (2011) 1.10
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
TREM-1 expression in macrophages is regulated at transcriptional level by NF-kappaB and PU.1. Eur J Immunol (2007) 1.07
M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) (2011) 1.03
Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol (2009) 1.00
Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Cancer Sci (2012) 0.96
Tumor-associated macrophages in thoracic malignancies. Lung Cancer (2013) 0.95
Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer (2011) 0.94
Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep (2011) 0.91
Lipopolysaccharide-induced up-regulation of triggering receptor expressed on myeloid cells-1 expression on macrophages is regulated by endogenous prostaglandin E2. J Immunol (2007) 0.90
A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol (2012) 0.87
Expression of TREM-1 is inhibited by PGD2 and PGJ2 in macrophages. Exp Cell Res (2010) 0.86
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog (2011) 0.86
Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int J Biochem Cell Biol (2012) 0.84
Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol (2012) 0.84
IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer (2012) 0.83
Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol (2007) 0.82
Macrophages: cancer therapy's double-edged sword. J Natl Cancer Inst (2012) 0.82
NS398 induces apoptosis in non-small cell lung cancer cells. J Cancer Res Clin Oncol (2011) 0.81